Press Release

Oncolytic Virus Therapy Market to grow with a CAGR of 23.10 %

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Oncolytic Virus Therapy Market.

According to TechSci Research report, “Global Oncolytic Virus Therapy Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Oncolytic Virus Therapy Market has valued at USD 15.38 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 23.10% through 2028. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

The presence of unmet medical needs within the field of cancer treatment is a significant driver of the demand for oncolytic virus therapy. Oncolytic virus therapy is often considered when patients have advanced or treatment-resistant cancers that do not respond well to standard treatments, such as chemotherapy or radiation therapy. This patient population represents a substantial unmet need. For certain cancer types, especially those with limited treatment options, oncolytic virus therapy offers a new and innovative approach. Patients and healthcare providers turn to these therapies when conventional treatments have been exhausted. Patients who experience cancer recurrence, where the cancer returns after initial treatment, often face limited options.

Oncolytic virus therapy may provide an alternative that can be effective against recurrent tumors. Some cancers develop in anatomically challenging locations where surgery or other interventions are difficult. It can be considered for these cases. Pediatric cancers and rare cancers may have limited treatment options due to their low prevalence. Oncolytic virus therapy can address unmet needs in these specific patient populations. Older patients and those with frail health may not be suitable candidates for aggressive treatments like surgery or high-dose chemotherapy. Oncolytic virus therapy can be considered as a more tolerable option for these individuals.

In August 2022, Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company at the forefront of allogeneic cell-based platforms for advancing oncolytic virus therapies, was delighted to announce that City of Hope has received approval from the U.S. Food and Drug Administration (FDA) to proceed with a physician-sponsored phase 1 clinical trial. This trial will utilize Calidi's licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (known as NeuroNova), a state-of-the-art therapeutic candidate. NeuroNova comprises tumor-targeting neural stem cells designed to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma, falling under Calidi's NNV-2 program. The upcoming phase 1 physician-sponsored clinical trial is planned as an open-label, non-randomized, and multicenter study. Its primary focus, once funding is secured, will be to assess the safety and tolerability of administering consecutive doses of NeuroNova to adult patients with recurrent, histologically confirmed high-grade gliomas (classified as WHO grade III or IV).

Immune response and clearance represent a notable challenge in the global oncolytic virus therapy market. The interaction between oncolytic viruses and the immune system can have a significant impact on the safety and efficacy of these therapies. The human immune system can recognize and respond to oncolytic viruses, potentially leading to their clearance before they effectively target and destroy cancer cells. Immune recognition can limit the therapeutic effect. The host immune system may mount an antiviral immune response against the oncolytic virus, preventing its replication and spread within the tumor. This immune reaction can hinder the therapeutic outcome. Pre-existing neutralizing antibodies in patients can render oncolytic viruses ineffective by blocking their ability to infect and replicate within tumor cells. Even if oncolytic viruses initially infect and replicate in tumor cells, the immune system can eliminate the infected cells, limiting the treatment's effectiveness. The immunosuppressive microenvironment within tumors can hamper the effectiveness of oncolytic viruses by inhibiting the host immune response. Tumor cells may release factors that suppress immune activity, allowing them to evade detection and destruction.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Oncolytic Virus Therapy Market

 

Global Oncolytic Virus Therapy Market is segmented based on Virus Type, Application, End User, and by region. 

Based on the Virus Type, Global Oncolytic Virus Therapy Market is segmented into Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others. Based on Region, North America held the largest share in the Global Oncolytic Virus Therapy Market. North America has a well-developed financial market that provides access to capital for biotechnology and pharmaceutical companies. Investment and funding opportunities are readily available, enabling the research and development of new therapies, including oncolytic virus treatments. Leading academic and research institutions in North America have made significant contributions to the field of oncolytic virus therapy. Researchers and scientists in the region have been pioneers in developing and advancing these therapies. The region's high incidence of cancer and the demand for more effective cancer treatments create a substantial market for oncolytic virus therapies. North American institutions and companies often engage in collaborations and partnerships, both domestically and internationally, to advance oncolytic virus therapy research and development. The region's leadership in the global pharmaceutical and biotechnology industries naturally extends to the field of oncolytic virus therapy. It has the influence and resources to shape global trends.

Some of the major companies operating in the Global Oncolytic Virus Therapy Market include:

  • Amgen Inc.
  • Merck & Co., Inc.
  • Oncolytics Biotech Inc.
  • PsiOxus Therapeutics Ltd.
  • Vyriad, Inc.
  • SillaJen Biotherapeutics
  • Cold Genesys Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Replimune Group Inc.
  • Genelux Corporation

 

Download Free Sample Report

Customers can also request 10% free customization on this report

 

“Certain areas, particularly in North America, are projected to exert significant demand for Oncolytic Virus Therapy. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Oncolytic Virus Therapy Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

"Global Oncolytic Virus Therapy Market by Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others), By Application (Solid Tumors, Hematological Malignancies), by End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), By Region, By Competition Forecast & Opportunities, 2018-2028F" has evaluated the future growth potential of Global Oncolytic Virus Therapy Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Oncolytic Virus Therapy Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News